Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

Glucagon analogs show promise as components of next-generation, multi-target, anti-obesity therapeutics. The biology of chronic glucagon treatment, in particular, its ability to induce energy expenditure and weight loss, remains poorly understood. Using a long-acting glucagon analog, G108, we demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Hope, David C.D., Hinds, Charlotte E., Lopes, Tatiana, Vincent, Matthew L., Shrewsbury, Jed V., Yu, Arthur T.C., Davies, Iona, Scott, Rebecca, Jones, Ben, Murphy, Kevin G., Minnion, James S., Sardini, Alessandro, Carling, David, Lutz, Thomas A., Bloom, Stephen R., Tan, Tricia M.M., Owen, Bryn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729826/
https://www.ncbi.nlm.nih.gov/pubmed/36384093
http://dx.doi.org/10.1016/j.xcrm.2022.100810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729826/
https://www.ncbi.nlm.nih.gov/pubmed/36384093
http://dx.doi.org/10.1016/j.xcrm.2022.100810

Ejemplares similares